These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 37030057)

  • 21. Hospital Prices for Physician-Administered Drugs for Patients with Private Insurance.
    Robinson JC; Whaley C; Dhruva SS
    N Engl J Med; 2024 Jan; 390(4):338-345. PubMed ID: 38265645
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The 340b Program, Contract Pharmacies, Hospitals, and Patients: An Evolving Relationship Impacting Health Care Delivery.
    Ruley M; Belcher M; Sayre H; Coustasse A
    Health Care Manag (Frederick); 2019; 38(4):311-321. PubMed ID: 31663869
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The 340B discount program: outpatient prescription dispensing patterns through contract pharmacies in 2012.
    Clark BL; Hou J; Chou CH; Huang ES; Conti R
    Health Aff (Millwood); 2014 Nov; 33(11):2012-7. PubMed ID: 25367997
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The 340B Program and High-Risk Prescribing of Oral Targeted Therapies for Advanced Prostate Cancer.
    Faraj KS; Oerline M; Kaufman SR; Dall C; Srivastava A; Caram MEV; Shahinian VB; Hollenbeck BK
    Urol Pract; 2024 Nov; 11(6):931-938. PubMed ID: 39196717
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Association Between the Percentage of US Drug Sales Subject to Inflation Penalties and the Extent of Drug Price Increases.
    Dickson S
    JAMA Netw Open; 2020 Sep; 3(9):e2016388. PubMed ID: 32915237
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comprehensive Legislative Reform to Protect the Integrity of the 340B Drug Discount Program.
    Zeta LM
    Food Drug Law J; 2015; 70(4):481-99, i. PubMed ID: 26827389
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Budgetary impact analysis of a primary care-based hepatitis C treatment program: Effects of 340B Drug Pricing Program.
    Jones EA; Linas BP; Truong V; Burgess JF; Lasser KE
    PLoS One; 2019; 14(3):e0213745. PubMed ID: 30870475
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development of a metrics dashboard for monitoring involvement in the 340B Drug Pricing Program.
    Karralli R; Tipton J; Dumitru D; Scholz L; Masilamani S
    Am J Health Syst Pharm; 2015 Sep; 72(17):1489-95. PubMed ID: 26294243
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Addressing financial toxicity in cancer treatment-An opportunity for the 340B drug pricing program.
    Faraj KS; Caram MEV; Shahinian VB; Hollenbeck BK
    Cancer; 2024 Sep; 130(18):3077-3081. PubMed ID: 38804732
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The impact of patient assistance programs and the 340B Drug Pricing Program on medication cost.
    Castellon YM; Bazargan-Hejazi S; Masatsugu M; Contreras R
    Am J Manag Care; 2014 Feb; 20(2):146-50. PubMed ID: 24738532
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tips for preparing for a 340B integrity audit.
    Wood W; Jorgenson J; Kelly W
    Healthc Financ Manage; 2012 Dec; 66(12):50-2. PubMed ID: 23252228
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Discounted Drugs for Needy Patients and Hospitals - Understanding the 340B Debate.
    Gellad WF; James AE
    N Engl J Med; 2018 Feb; 378(6):501-503. PubMed ID: 29365283
    [No Abstract]   [Full Text] [Related]  

  • 33. 340B Drug Pricing Program: The Expansion and Its Effect on Cancer Care.
    Fauer A; Friese CR
    Clin J Oncol Nurs; 2019 Apr; 23(2):217-219. PubMed ID: 30880808
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Using 340B drug discounts to provide a financially sustainable medication discharge service.
    Wu T; Williams C; Vranek K; Mattingly TJ
    Res Social Adm Pharm; 2019 Jan; 15(1):114-116. PubMed ID: 29606609
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Minimum-distance requirements could harm high-performing critical-access hospitals and rural communities.
    Casey MM; Moscovice I; Holmes GM; Pink GH; Hung P
    Health Aff (Millwood); 2015 Apr; 34(4):627-35. PubMed ID: 25847646
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The role of critical access hospital status in mitigating the effects of new prospective payment systems under Medicare.
    Dalton K; Slifkin RT; Howard HA
    J Rural Health; 2000; 16(4):357-70. PubMed ID: 11218322
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The 340B Program and oral specialty drugs for advanced prostate cancer.
    Faraj KS; Kaufman SR; Oerline M; Herrel LA; Maganty A; Caram MEV; Shahinian VB; Hollenbeck BK
    Cancer; 2024 Jun; 130(12):2160-2168. PubMed ID: 38395607
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of Generic Prescribing Patterns Among 340B-Eligible and Non-340B Prescribers in the Medicare Part D Program.
    Dickson S; James K
    JAMA Health Forum; 2023 May; 4(5):e231026. PubMed ID: 37204805
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Maintaining qualification for 340B.
    Gricius RF; Wong D
    Healthc Financ Manage; 2016 Mar; 70(3):70-5. PubMed ID: 27183761
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Commercial markups on pediatric oncology drugs at 340B pediatric hospitals.
    Liu ITT; Wang J; Sarpatwari A; Kesselheim AS; Feldman WB
    Pediatr Blood Cancer; 2024 Sep; 71(9):e31158. PubMed ID: 38970222
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.